INV vs JRI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in fundamental health. While revenue growth is robust at 80.30%, the valuation is disconnected from reality with a Price/Sales ratio of 169.02 and a catastrophic operating margin of -3859.12%. Despite a 'strong_buy' analyst consensus from a very small sample, heavy insider selling of $10.16M and a bearish technical trend suggest a high-risk speculative environment.
The deterministic health profile for JRI is critically weak, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental deterioration. While the fund offers an attractive dividend yield of 12.51%, the 90% payout ratio suggests limited sustainability and potential capital erosion. The current price of $12.81 trades at a premium to the growth-based intrinsic value of $12.32, and the technical trend is completely bearish (0/100). Overall, the combination of poor financial health scores and negative price momentum outweighs the high yield.
Compare Another Pair
Related Comparisons
INV vs JRI: Head-to-Head Comparison
This page compares Innventure, Inc. (INV) and Nuveen Real Asset Income and Growth Fund (JRI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.